安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated
- FDA grants accelerated approval to tarlatamab-dlle for lung cancer
On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc ) for extensive stage small cell lung cancer (ES-SCLC) with disease
- Practical management of adverse events in patients receiving tarlatamab . . .
Tarlatamab is a bispecific T‐cell engager (BiTE) immunotherapy that binds both delta‐like ligand 3 (DLL3) on cancer cells and the cluster of differentiation 3 (CD3) molecule on T cells
- Tarlatamab Phase 3 Results: New SCLC Standard at ASCO 2025
Tarlatamab achieved a median overall survival (mOS) of 13 6 months compared to 8 3 months with chemotherapy The hazard ratio (HR) was 0 6, with a p-value less than 0 001, indicating statistical significance At 12 months from randomization, 62% of tarlatamab patients were alive, compared to 37% in the chemotherapy group
- Tarlatamab-dlle - NCI - National Cancer Institute
Tarlatamab-dlle is approved to treat: Small cell lung cancer It is used in adults with extensive-stage cancer that got worse during or after treatment with platinum-based chemotherapy Tarlatamab-dlle is approved under FDA’s Accelerated Approval Program
- Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages . . .
Tarlatamab, marketed as Imdelltra, is a bispecific T-cell engager (BiTE®) antibody that harnesses the body’s immune system to fight small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine tumors
- Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy
Tarlatamab is a bispecific T-cell engager that targets both delta-like ligand 3 (DLL3), which is expressed on the surface of cancer cells in most patients, and CD3, which is found on T-cells
- Tarlatamab Significantly Improves Survival in Patients With Small Cell . . .
Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy
|
|
|